Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Dec;19(12):1793-1797.
doi: 10.1111/dom.13022. Epub 2017 Jul 25.

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly

Affiliations
Comparative Study

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly

Jonathan E Shaw et al. Diabetes Obes Metab. 2017 Dec.

Abstract

The range of glycated haemoglobin (HbA1c) responses and characteristics associated with above-average response to exenatide twice daily and once weekly were examined. Data were pooled from 8 exenatide-twice-daily and 5 exenatide-once-weekly studies. A baseline HbA1c-corrected measure of change in HbA1c after 24 weeks identified high, average and low responses. Multiple linear regression and multivariate generalized estimating equation models identified factors associated with high response. Among 2355 participants (exenatide twice daily, n = 1414; exenatide once weekly, n = 941), baseline HbA1c correlated with change in HbA1c (P < .0001). Across baseline HbA1c levels, the 25th to 75th percentile of HbA1c change ranged from -0.3% to -3.2% with exenatide twice daily and from -0.5% to -3.6% with exenatide once weekly. Asian ethnicity and older age were significantly associated with high response to exenatide twice daily; no factors were significantly associated with response to exenatide once weekly. These data provide clinically useful information for estimating the likelihood that, depending on baseline HbA1c, an individual can achieve HbA1c goals. The association between Asian ethnicity, age and high response to exenatide twice daily may relate to the specific effects of exenatide twice daily on postprandial glucose.

Keywords: exenatide once weekly; exenatide twice daily; glucagon-like peptide-1 receptor agonist; predictors.

PubMed Disclaimer

Conflict of interest statement

J. E. S. has received honoraria for advisory boards and lectures from AstraZeneca, BGP Products, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. B. G. has received honoraria for advisory boards and lectures from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. J. H. is a consultant for AstraZeneca. E. H. is an employee of AstraZeneca. G. S. has received honoraria for advisory boards and lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi, and Takeda.

Figures

Figure 1
Figure 1
Box and whiskers plot of the change in HbA1c for a given baseline HbA1c. Midline represents the 50th percentile, the box represents the 25th and 75th percentiles, and whiskers represent the 10th and 90th percentiles

Similar articles

Cited by

References

    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient‐centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149. - PubMed
    1. McCormack PL. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. Drugs. 2014;74:325–351. - PubMed
    1. Kayaniyil S, Lozano‐Ortega G, Bennett HA, et al. A network meta‐analysis comparing exenatide once weekly with other GLP‐1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Ther. 2016;7:27–43. - PMC - PubMed
    1. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly‐(D,L‐lactide‐co‐glycolide) microspheres produced an investigational long‐acting once‐weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13:1145–1154. - PMC - PubMed
    1. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open‐label, non‐inferiority study. Lancet. 2008;372:1240–1250. - PubMed

Publication types

MeSH terms